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Protocol
AbstrACt
Introduction Fatigue is one of the most common 
and disabling symptoms in end-stage kidney disease, 
particularly among in-centre haemodialysis patients. This 
two-arm parallel group feasibility randomised controlled 
trial will determine whether a fully powered efficacy trial 
is achievable by examining the feasibility of recruitment, 
acceptability and potential benefits of a cognitive-
behavioural therapy (CBT)-based intervention for fatigue 
among in-centre haemodialysis patients.
Methods We aim to recruit 40 adult patients undergoing 
in-centre haemodialysis at secondary care outpatient 
dialysis units, who meet clinical levels of fatigue. Patients 
will be randomised individually (using a 1:1 ratio) to either 
a 4–6 weeks’ CBT-based intervention (intervention arm) 
or to a waiting-list control (control arm). The primary 
feasibility outcomes include descriptive data on numbers 
within each recruiting centre meeting eligibility criteria, 
rates of recruitment, numbers retained postrandomisation 
and treatment adherence. To assess the potential 
benefits of the cognitive-behavioural therapy for renal 
fatigue intervention, secondary self-report outcomes 
include measures of fatigue severity (Chalder Fatigue 
Questionnaire), fatigue-related functional impairment 
(Work and Social Adjustment Scale), sleep quality 
(Pittsburgh Sleep Quality Index), depression (Patient 
Health Questionnaire-9) and anxiety (Generalised Anxiety 
Disorder-7). Changes in fatigue perceptions (Brief Illness 
Perception Questionnaire), cognitive and behavioural 
responses to fatigue (Cognitive and Behavioural Responses 
to Symptoms Questionnaire), sleep hygiene behaviours 
(Sleep Hygiene Index) and physical activity (International 
Physical Activity Questionnaire–short form) will also be 
explored. These self-report measures will be collected 
at baseline and 3 months postrandomisation. Nested 
qualitative interviews will be conducted postintervention 
to explore the acceptability of the intervention and identify 
any areas in need of improvement. The statistician and 
assessor will be blinded to treatment allocation.
Ethics and dissemination A National Health Service 
(NHS) Research Ethics Committee approved the study. Any 
amendments to the protocol will be submitted to the NHS 
Committee and study sponsor.
trial registration number ISRCTN91238019;Pre-results.
IntroduCtIon 
End-stage kidney disease (ESKD) is a chronic 
disease of the kidneys, characterised by 
inadequate renal functioning, where renal 
replacement therapy (RRT) is necessary to 
sustain life.1 Haemodialysis (HD) is the most 
common RRT modality, filtering toxins out 
of the blood via an artificial extracorporeal 
blood circuit. A typical HD patient will be 
required to attend dialysis sessions three times 
a week for 3–4 hours each time.2 On average, 
patients with renal disorder experience 14 
symptoms, with fatigue emerging as one of the 
most persistent and debilitating symptoms.3 4 
Fatigue is a complex and subjective symptom 
characterised by extreme and persistent tired-
ness resistant to rest and recuperation.5–7 
Forty-nine to 92% of dialysis patients suffer 
from fatigue.3 Fatigue is a substantial contrib-
utor to impaired functioning and quality of 
life, and recent evidence suggests that it has 
also implications for clinical outcomes8–14; 
strengths and limitations of this study
 ► This is the first feasibility trial assessing the 
feasibility, acceptability and potential benefits of a 
psychological intervention for the management of 
fatigue among in-centre haemodialysis patients.
 ► The mixed-methods approach will help to evaluate 
comprehensively and in-depth the feasibility and 
acceptability of the cognitive-behavioural  therapy 
for renal fatigue (BReF) intervention; the qualitative 
data will complement the quantitative findings and 
help to identify areas in need of improvement.
 ► The BReF intervention was developed systematically, 
using theory and evidence, with substantial input 
from patient and public representatives.
 ► As this is a feasibility trial, it is not powered to detect 
efficacy.
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yet, it is often under-recognised and undertreated by 
healthcare professionals, perceived as a normal conse-
quence of the illness and treatment burden.15 16 
Current management in the form of pharmacological 
treatments or exercise is ineffective17 18 and no theo-
ry-driven and evidence-based psychological interventions 
aimed at fatigue for this group currently exist, although 
there is some promising evidence for some improvements 
in fatigue following psychological interventions not 
aimed at fatigue specifically.19 As the aetiology of fatigue 
in patients with renal disorder is still largely unknown, no 
consistent treatment model exists.8 20
There is increasing recognition regarding the impor-
tance of psychological factors in the perpetuation and 
maintenance of fatigue in other long-term physical 
conditions.21–26 For example, in multiple sclerosis (MS), 
negative fatigue beliefs, such as catastrophising about the 
consequences of fatigue, embarrassment about fatigue 
and belief that fatigue is a sign of physical damage; and 
unhelpful behaviours in response to fatigue, like exces-
sive resting or overdoing things followed by long resting 
periods to recover; were found to be strongly associated 
with fatigue, above and beyond the role of demographic 
and clinical factors, such as neurological impairment 
and remission status.22 On the other hand, social support 
may act as a buffer to fatigue perpetuation.27 An under-
standing of the contribution of these factors to fatigue 
has translated into successful psychological interven-
tions, leading to clinically significant improvements in 
fatigue severity and fatigue-related functional impair-
ment.28 29 There is, in fact, extensive evidence in support 
of cognitive-behavioural therapy (CBT) for adjustment 
and the management of symptoms, like fatigue, in the 
context of long-term physical conditions, such as cancer 
and MS,30 31 despite being originally developed for the 
treatment of mood disorders.32 33 CBT is a structured, 
tailored and time-limited talking therapy that focuses on 
changing negative beliefs and unhelpful behaviours, as 
well as relaxation techniques, stress management and 
mindfulness to foster resilience.33 34
We conducted preliminary work, consisting of prospec-
tive and qualitative studies, which revealed the importance 
of cognitive and behavioural factors in the experience 
of fatigue in ESKD, in line with the findings from other 
long-term physical conditions. To date, the effectiveness 
of CBT specifically for fatigue has not been examined in 
this population, yet, a similar approach may also be useful 
here. Based on the findings from these precursor studies 
and patient and public involvement (PPI) input, we 
adapted an existing CBT approach initially developed by 
one of the authors (RMM) for fatigue in MS. According 
to this renal fatigue treatment formulation, which inte-
grates biological and psychosocial factors; there are a 
number of factors that may act as triggers of fatigue 
in this patient population, such as anaemia and HD. 
While these factors trigger initial symptoms of fatigue, 
one’s thoughts, emotions and behaviours in response to 
fatigue may maintain and perpetuate fatigue, potentially 
leading to a vicious cycle of negative illness and fatigue 
beliefs, increased distress and maladaptive behaviours, as 
displayed in figure 1. The factors maintaining and perpet-
uating fatigue are targeted in CBT.
Figure 1. Cognitive-behavioural therapy model of renal fatigue. This diagram illustrates the different clinical, social situational 
and psychological factors that contribute to fatigue in this setting.
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objectives
A feasibility design was deemed necessary to determine 
whether a full-scale randomised controlled trial (RCT) 
is feasible, by considering numbers meeting eligibility 
criteria, rates of recruitment and retention postrandomi-
sation, floor/ceiling effects that might affect sensitivity 
to change; as well as by identifying any intervention-spe-
cific issues, particularly occurrence of adverse events and 
timing burden. The following aims will be addressed in 
this feasibility RCT:
 ► Objective 1: to estimate rates of recruitment and 
retention.
 ► Objective 2: to estimate willingness to be randomised.
 ► Objective 3: to explore the level of adherence to the 
intervention (intervention arm only).
 ► Objective 4: to estimate the standard deviation (SD) of 
fatigue in this patient population in order to compute 
a more robust estimate of the sample size required for 
an efficacy trial.
 ► Objective 5: to preliminary assess the psychometric 
properties of the self-report instruments used.
 ► Objective 6: to explore the potential benefits of 
the intervention at reducing fatigue severity and 
fatigue-related functional impairment as compared 
with the waiting-list control.
 ► Objective 7: to explore the potential benefits of the 
intervention at reducing depression and anxiety and 
improving sleep quality as compared with the wait-
ing-list control.
 ► Objective 8: to examine change in fatigue-related 
cognitions and behaviours, and whether their effect 
differs between the intervention and control arm.
 ► Objective 9: to qualitatively explore patient percep-
tions of the acceptability and usefulness of the inter-
vention and identify areas of improvement for a future 
full-scale trial.
 ► Objective 10: to explore any intervention-specific 
issues, particularly setting, mode of delivery of the 
intervention and acceptable number of sessions/
chapters.
MEthods
design
A two-arm parallel group feasibility RCT. There will be 
one follow-up assessment at 3-month postrandomisation. 
A nested-qualitative study will evaluate patients’ experi-
ences with the intervention.
setting and participants
Outpatient HD patients will be recruited from two 
National Health Service (NHS) sites in England.
Inclusion and exclusion criteria
Participants are eligible for the study if they:
 ► are >18 years of age
 ► have a confirmed ESKD diagnosis
 ► are experiencing clinical levels of fatigue 
defined as scoring >18 on the Chalder Fatigue 
Questionnaire (CFQ), when using the continuous 
scoring35 36
 ► have full verbal and written proficiency in English
 ► are receiving in-centre HD
 ► length of time on dialysis >90 days
 ► are willing and able to take part in the study and 
intervention.
Patients will be excluded if they:
 ► do not provide informed consent or refuse to be 
randomised
 ► have any known cognitive impairments
 ► have a severe mental health disorder, for example, 
psychosis and bipolar disorder
 ► do not have full verbal and written proficiency in 
English
 ► are currently receiving psychotherapy
 ► are currently participating in any other intervention 
trial
 ► are failing on dialysis and approaching end of life 
(supportive care/palliative care pathway)
 ► have a fatigue (CFQ) score below the cut-off at the 
prerandomisation assessment (spontaneous improve-
ment after screening).
Patients will not be screened for anaemia. Levels of 
haemoglobin and haematocrit are generally maintained 
within recommended ranges.17 Additionally, there is 
evidence for a ceiling effect of anaemia management on 
fatigue37 and improvements in fatigue are often below a 
clinically meaningful threshold, particularly in patients 
on dialysis.38 Nonetheless, the role of anaemia-related 
factors will be examined in the exploratory analysis and 
may lead to changes to the inclusion/exclusion criteria 
for a future efficacy trial.
Flow of recruitment and participant timeline
Recruitment will take place from October 2017 to July 
2018. Patients interested in participating will be given a 
participant information sheet, screening questionnaire, 
consisting of sociodemographic and illness-related ques-
tions and the CFQ; an informed consent form and a 
freepost envelope. Potential participants will be given a 
minimum of 24 hours to establish if they would like to take 
part. Following consent, eligible participants will receive 
the baseline questionnaire, and will be randomised after 
the completion of the baseline questionnaire. Partici-
pants who score below the fatigue cut-off at the prerando-
misation assessment will be excluded.
Participants will be informed of the outcome of the 
randomisation process over the phone and will receive 
confirmation of their treatment allocation and mate-
rials via post. We anticipate the participant’s journey 
through the study will last approximately 4–5 months, 
as summarised in figure 2, with approximately 1 month 
dedicated to screening and randomisation. The interven-
tion will last between 4 and 6 weeks, depending on each 
participant’s needs. Participants are expected to complete 
one session per week. Follow-up data will be collected 
at 3 months postrandomisation (T1). On completion 
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of the postintervention questionnaire, a subsample of 
participants will be invited to take part in the qualitative 
interview. After completion of follow-up assessments at 
T1, participants in the control condition will receive the 
intervention manual and tasks workbook via post.
randomisation, allocation concealment and blinding
Participants will be randomised in a 1:1 ratio to receive 
either the cognitive-behavioural therapy for renal fatigue 
(BReF) intervention or to the waiting-list control. Partic-
ipants will be randomised at the individual level. Rando-
misation will be stratified by centre and randomly varying 
block sizes will be used to maintain balance of numbers 
in each arm across the period of recruitment while main-
taining allocation concealment. King’s College London’s 
independent randomisation service will be used. Because 
the randomisation sequence is automated in real time, the 
allocation sequence is concealed from researchers. The 
trial coordinator will receive an automated email with the 
outcome of the randomisation procedure. The nature of 
the trial is such that blinding of participants cannot be 
achieved. Follow-up outcomes will be completed inde-
pendently by participants by post or online. If baseline 
or follow-up questionnaires are not completed, then 
Figure 2 Anticipated flow of participants through the study. Number of patients approached for screen, those who consented, 
and those who were assessed for eligibility will be recorded. Eligible patients will be invited to complete a baseline questionnaire 
(T0). After completion of the baseline questionnaire, participants will be randomised. Participants in the intervention arm will 
receive the intervention over 4–6 weeks. All participants will complete a follow-up questionnaire at 3 months postrandomisation 
(T1). Participants in the intervention arm will be invited to take part in a qualitative evaluation interview at the end of their 
involvement in the study. After completion of the follow-up questionnaire, participants in the control arm will receive the 
intervention materials.
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participants will receive reminder emails or phone calls 
and an assistance-based visit at the dialysis unit, by an 
independent researcher, who has not been involved in 
the intervention delivery. The statistician will remain 
blinded to treatment allocation.
breF intervention
The intervention is a tailored CBT-based self-manage-
ment intervention with therapist support. The purpose 
of this intervention is to target individuals’ fatigue beliefs 
and behaviours in order to facilitate coping with renal 
fatigue (ReF). Further detail on the intervention can be 
found in figure 3. Therapist guidance was deemed neces-
sary to facilitate engagement with the programme, partic-
ularly in the formulation of a personal biopsychosocial 
model of fatigue and identification of unhelpful thoughts 
and behaviours.39–41
The development of the CBT-based intervention was 
systematic, based on the findings of reviews and qualita-
tive and prospective studies, with substantial input from 10 
patient and public representatives and a multidisciplinary 
team of health psychologists, clinical psychologists and 
nephrologists. The structure and content of the manual 
was drafted based on previous CBT interventions devel-
oped by one of our authors (RMM), such as ‘Managing 
Your Multiple Sclerosis Fatigue: A Cognitive behavioural therapy 
manual’ and ‘Improving Distress in Dialysis’42–46 and other 
sources.47–49
Participants will be provided with a structured CBT 
manual and a tasks workbook, including goal-setting 
sheets. This will be accompanied by three to five sessions 
with either a primary researcher who has a background in 
health psychology, basic CBT training and experience in 
working with fatigued patient groups (FP) or a registered 
health psychologist working in the renal setting (HC). 
In accordance with CBT principles, participants will be 
encouraged to complete tasks between sessions. Comple-
tion of these tasks has been found to be predictive of CBT 
outcomes.50 51
The manual consists of 10 chapters, accompanied by 
a tasks workbook for each session. Please see table 1 for 
the content of each chapter and associated tasks to be 
completed between sessions. The programme consists of 
two units, the basic unit (level 1) or the advanced unit 
(level 2). In the basic unit, participants will cover four 
chapters out of the manual, three will be accompanied 
by therapist sessions and one will be selected according to 
participants’ needs, established in the assessment. Partici-
pants, engaging well in the first two sessions, will be given 
the opportunity to cover an additional two chapters with 
the therapist over the phone (level 2). Engagement will 
be discussed in clinical supervision, and will be assessed 
through, for example, completion of between session 
tasks and focus maintained during the sessions. The brief 
and stepped structure of the intervention was chosen to 
meet patients’ needs, particularly their fatigability and 
potential concentration difficulties, according to the 
practical considerations previously raised with regards 
to the delivery of CBT in MS.52 Sessions will be guided 
by participants’ needs, identified through the self-moni-
toring tasks.
The first and last sessions will be face-to-face lasting 
1 hour, while the remaining sessions will be over the 
phone, and will last 30 min. A combination of face-to-face 
and telephone sessions has been previously suggested 
for CBT in MS, to overcome possible limitations of indi-
vidual delivery methods.52 Sessions will be scheduled at 
Figure 3 Structure and content of the intervention. The intervention will follow a stepped approach over 4–6 weeks, 
accompanied by 3–5 sessions with a therapist. In level 1, participants will cover chapters 1, 2, a relevant chapter identified in 
the assessment and chapter 8. Level 2 focuses on cognitive therapy.
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times that suit the participants. Face-to-face sessions will 
be conducted in a private environment. For the tele-
phone sessions, participants will be encouraged to have 
the sessions in a quiet and private environment and allo-
cate sufficient time not to feel rushed. Please see the 
Template for Intervention Description and Replication 
(TIDieR)checklist for a summary (table 2).
Waiting-list control (control arm)
Participants allocated to the control arm of the study will 
receive their usual renal care, consisting of attending dial-
ysis. As part of this feasibility trial, what constitutes usual 
care will be monitored to determine a control arm for a 
future efficacy trial and to handle potential contamina-
tion between the arms. After completion of the follow-up 
questionnaire, participants in the control group will 
receive the intervention manual and tasks workbook, 
but will not receive therapist support sessions. To mini-
mise attrition from the control group, participants will be 
called to remind them that they can gain access to the 
programme in the weeks that follow.
Clinical supervision
FP and HC will receive training on how to deliver the 
therapist support sessions from RMM, with approxi-
mately 3–4 hours of face-to-face contact, in addition to 
audio-recorded role-playing sessions with feedback. FP 
and HC will receive continuous supervision throughout 
the intervention from RMM, following the framework 
developed to support the delivery of psychological thera-
pies with persistent physical conditions.53 This will involve 
reflection and discussion of the sessions, feedback on the 
audio-recorded sessions and case management, partic-
ularly following the initial session with each participant 
in terms of the treatment plan and subsequently discus-
sions around each participant’s progress over the course 
of the intervention and progression to the level 2 sessions.
Intervention fidelity
Two therapists will deliver all the intervention sessions 
following the detailed and structured manual developed 
for the patients. With permission from the participants, 
sought on the consent form, therapy sessions will be 
audio-recorded and a random sample assessed for fidelity 
during supervision by RMM.
data collection and feasibility outcomes
The primary focus of this trial is the feasibility of the BReF 
intervention.
Primary feasibility outcomes
Feasibility will be assessed by collecting descriptive data 
on recruitment and retention rates and willingness to 
be randomised according to Consolidated Standards of 
Reporting Trials feasibility and pilot trial guidelines.54 
In the intervention arm, the degree of adherence to the 
intervention will also be assessed by recording comple-
tion of the chapter selected in session 1 and completed 
by participants independently in week 3 and the between 
sessions tasks, as well as recording of attendance at ther-
apist sessions (ie, did not attend (DNA’s) and adherence 
to the assigned session time). Uptake of and adherence 
Table 1 Summary of the content of the BReF manual
Chapter Content
Between sessions 
task
ReF explained Understanding 
ReF and alternative 
explanations
A model for ReF
Assessment of fatigue
Fatigue self-
monitoring
Finding 
balance in 
activities and 
rest
Patterns of rest and 
activity and its effects 
on the body
Planning activity and 
rest
Exercise
Activity difficulty task
Activity and rest goal 
sheet
Improving 
sleep
Sleep hygiene
Maladaptive sleep 
patterns
Improving sleep
Sleep, activity and 
rest goal sheet
Learning to 
relax
Diaphragmatic 
breathing
Progressive Muscle 
Relaxation (PMR)
Relaxation training: 
step-by-step
Relaxation diary
Coping with 
emotions
Strategies to cope 
with negative emotions
Self-assessment of 
negative emotions
Expressing emotions
Coping with negative 
emotions goal sheet
Managing 
stress
General tips to reduce 
the impact stress has 
on your life 
Managing controllable 
and uncontrollable 
stressors
Mindfulness
Managing stress 
goal sheet
Making use 
of your social 
support
Creating a support 
network
Disclosure versus 
keeping it to self
Social comparisons
Social support goal 
sheet
Becoming 
aware of your 
thinking
Common unhelpful 
thoughts
Identifying unhelpful 
thinking
Thought record
Changing 
your thinking
Identifying alternative 
thoughts
Alternative thoughts 
goal sheet
Preparing for 
the future
Sustaining and 
building on 
improvements
Developing future 
goals
Tips for everyday life
Long-term goals 
worksheet
BReF, cognitive-behavioural therapy for renal fatigue; PMR, 
progressive muscle relaxation; ReF, renal fatigue.
 o
n
 7 June 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-020842 on 8 March 2018. Downloaded from 
7Picariello F, et al. BMJ Open 2018;8:e020842. doi:10.1136/bmjopen-2017-020842
Open Access
to the level 2 sessions will also be recorded. Given the 
exploratory nature of this trial, the number of completed 
intervention components will be assessed, this may help 
to identify an adherence cut-off for a future efficacy trial.
secondary self-reported patient outcomes
Self-reported patient outcomes will also be collected at 
baseline (T0) and 3 months postrandomisation (T1) 
via post or online. The assessment schedule completed 
by patients is summarised in table 3 and the self-report 
instruments used are described below.
Fatigue severity
Chalder Fatigue Questionnaire (CFQ)35 measures fatigue 
severity via 11 items scored against a 4-point Likert-type 
response scale. Scores are assigned for each response, 
using continuous scoring from 0 to 3. A cut-off of >18 
defines a fatigue case.35 36 Higher scores represent greater 
fatigue severity. The total score will be used here following 
recent psychometric evidence.55 56 This scale displays 
Table 3 Schedule of assessments
Assessment
Time
Screening
Baseline 
(T0)
Postintervention 
(T1)
CFQ x x x
WSAS x x
PHQ-9 x x
GAD-7 x x
PSQI x x
BIPQ x x
CBSQ x x
SHI x x
IPAQ-short x x
CCI x
Sociodemographic 
characteristics
x x
Clinical 
characteristics
x x
Biochemical 
outcomes
x x
Self-reported 
adverse events
x
Self-reported 
treatments for 
distress or fatigue 
during study
x
Qualitative 
interviews
x
BIPQ, Brief Illness Perceptions Questionnaire; CBSQ, Cognitive 
and Behavioural Responses to Symptoms Questionnaire; CCI, 
Charlson Comorbidity Index; CFQ, Chalder Fatigue Questionnaire; 
GAD-7, Generalised Anxiety Disorder-7; IPAQ-short, International 
Physical Activity Questionnaire -short form; PHQ-9, Patient Health 
Questionnaire-9; PSQI, Pittsburgh Sleep Quality Index; SHI, Sleep 
Hygiene Index; WSAS, Work and Social Adjustment Scale. 
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excellent psychometric properties35 57 and has been vali-
dated among patients on HD.56
Fatigue-related functional impairment
Work and Social Adjustment Scale (WSAS)58 consists of five 
items that correspond to impairment in work, home 
management, social activities, private leisure activities and 
relationships as consequence of an illness or symptom, in 
this case fatigue. Higher scores indicate greater impair-
ment. It has good psychometric properties58 and has been 
previously used with patients on HD.59
Depression
Patient Health Questionnaire-9 (PHQ-9)60 measures depres-
sion over the last 2 weeks via a nine-item scale and an 
additional item to assess the impact of depression on 
functioning. Each item is scored from 0 (not at all) to 
3 (nearly every day), with greater scores representing 
greater severity of depression. Depression severity cut-offs 
are available. The functional item is rated from ‘Not at 
all difficult’ to ‘Extremely difficult’. The PHQ-9 displays 
excellent psychometric properties and is responsive to 
change.61 62 The PHQ-9 has been validated in HD.63
Anxiety
Generalised Anxiety Disorder-7 (GAD-7)64 measures anxiety 
over 2 weeks, via a seven-item scale, and an additional item 
to assess the impact of anxiety on functioning. Each item 
is scored from 0 (not at all) to 3 (nearly every day), with 
greater scores representing greater severity of anxiety. 
Anxiety severity cut-offs are available. The functional 
item is rated from ‘Not at all difficult’ to ‘Extremely diffi-
cult’. The PHQ-9 displays excellent psychometric prop-
erties.64 65 This instrument has been used across chronic 
conditions, including HD patients.42
Sleep quality
Pittsburgh Sleep Quality Index (PSQI)66 measures seven 
components of sleep quality (subjective sleep quality, 
sleep latency, sleep duration, sleep efficiency, sleep distur-
bance, use of sleep medication and daytime dysfunction) 
over a 1 month time interval, via 19 items. Items are scored 
on an interval scale from 0 to 3. The scores of the compo-
nents are then summed to obtain a global sleep quality 
score, ranging from 0 to 21. Higher scores indicate worse 
sleep quality. This scale displays satisfactory psychometric 
quality across patient populations66 67 and is widely used 
and has been validated.68
Process variables
Fatigue perceptions
Brief Illness Perceptions Questionnaire (BIPQ)69 relies on a 
single-item approach to measure fatigue perceptions. 
It is a shorter version of the original Illness Perception 
Questionnaire (IPQ),70 with moderate to good associa-
tions between the two.69 Five of the items assess cognitive 
illness/symptom representations (consequences, time-
line, personal control, treatment control and identity), 
two of them assess emotional representation (concern 
and emotions) and one item assesses illness/symptom 
comprehension. The items are rated using a response 
scale of 0–10. The psychometric properties of this 
measure have been assessed using samples from several 
illness groups, including renal disease,69 displaying satis-
factory quality.
Cognitive and behavioural responses to fatigue
Cognitive and Behavioural Responses to Symptoms Question-
naire (CBSQ)71 includes five cognitive subscales; fear avoid-
ance, embarrassment avoidance, catastrophising about 
symptoms, beliefs that symptoms signal damage to the 
body (damage beliefs) and symptom focus, scored from 
strongly disagree (0) to strongly agree (4). There are 
also two behavioural subscales; resting and avoidance of 
activity and all-or-nothing behaviour. All items are scored 
on a five-point frequency scale ranging from never (0) to 
all the time (4). Item scores are added from each subscale 
to obtain a total score. Across studies, this instrument 
displays acceptable psychometric quality72 and it has 
been used with different patient populations, including 
patients on HD.59
Sleep hygiene behaviours
Sleep Hygiene Index (SHI).73 measures sleep-related 
behaviours via 13 items. Each item is rated on a five-point 
scale, ranging from 0 (never) to 4 (always). Total scores 
range from 0 to 52, with higher scores representing 
poorer sleep hygiene. This scale displays adequate reli-
ability and validity.73 74 However, it has not yet been vali-
dated in kidney failure.
Physical activity
International Physical Activity Questionnaire–short form 
(IPAQ-SF).75 measures self-reported weekly time spent on 
physical activities (walks, physical exertion of moderate 
and vigorous intensities) and inactivity (sitting) via seven 
items. The questionnaire can be scored categorically 
according to developed cut-offs to classify individuals into 
low, moderate or high physical activity groups; or it can 
be scored continuously. Responses can be converted to 
metabolic equivalent task minutes per week (METmin/
week), according to the IPAQ scoring protocol. MET 
scores across the three subcomponents can be summed 
to indicate overall physical activity.75 The IPAQ is the most 
widely validated questionnaire, however, with some incon-
sistent evidence on its reliability and validity.76 Given its 
brevity, simplicity and extensive use across research, it was 
selected here to measure physical activity.
Adverse events
Information about occurrence of serious adverse events 
since the start of the study will be collected by self-report 
postintervention, according to good clinical practice 
guidelines. Adverse events will be flagged up to the trial 
management team and participants will be contacted to 
further assess the adverse event and its relationship to the 
study.
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other treatments
Participants will be asked whether they have received any 
pharmacological, psychological or exercise-based treat-
ment for depression and/or anxiety and/or fatigue in 
addition to BReF since starting the study.
demographic, social situational and clinical characteristics
At baseline, sociodemographic characteristics, including: 
gender, age, ethnicity, marital status, employment status, 
education, living arrangements, exercise, smoking status 
and alcohol consumption; and clinical characteristics, 
including: dialysis vintage and receipt of anaemia treat-
ments will be collected via self-report.
Extra renal comorbidity will be assessed at baseline 
by consultant nephrologists using the Charlson Comor-
bidity Index (CCI).77 This instrument is a weighted index 
that takes into account the number and the seriousness 
of comorbid diseases and can be adjusted for age. The 
method of classifying comorbidity provides a simple, 
readily applicable and valid method of estimating risk 
of death from comorbid disease for use in longitudinal 
studies.77 The CCI has been previously used with and 
determined suitable for patients on dialysis.78 79
Clinical information, including: dialysis adequacy (urea 
reduction ratio), interdialytic weight gain, haemoglobin, 
ferritin, serum albumin, creatinine, urea, phosphate, 
potassium, calcium, C reactive protein and primary renal 
diagnosis will be extracted from patients’ medical notes at 
baseline (T0) and postintervention (T1).
Qualitative interviews
To complement the quantitative process evaluation and 
further explore the acceptability of the intervention, in 
line with current MRC process evaluation guidelines,80 
qualitative interviews will be conducted with a subgroup 
of participants from the intervention group at 3 months 
postrandomisation (T1). The interviews will be semi-
structured and will be conducted over the phone or 
face-to-face, in a private environment. The interviews 
will be conducted by an independent researcher, who 
has not been involved in the intervention delivery. The 
main aim of the interviews will be to gather participants’ 
experiences of the intervention, to identify areas of 
improvement. Purposive maximum variation sampling 
will be employed to ensure variability of the sample 
across a range of sociodemographic and clinical char-
acteristics,81 in particular: age, gender, ethnicity, dialysis 
vintage, degree of adherence to the intervention, degree 
of improvements in outcomes following the intervention. 
A minimum of 10 interviews will be conducted, until data 
saturation is reached, meaning the point where no new 
data is obtained with every new interview.82
sample size
The renal service of King’s College Hospital has approx-
imately 550 patients on HD and Lister Hospital has 
approximately 510 patients on HD, in which we expect 
to be able to approach 636 (60%) during the recruitment 
period. Past psychological research in patients on dialysis, 
conducted by the team, suggest consent rates between 
50% and 70%, assuming a more conservative uptake 
of 40%, 254 patients are expected to be screened, with 
approximately 30% (n=76) expected to meet the inclu-
sion criteria, including around half reporting clinical 
levels of fatigue.59 Assuming 50% of those eligible will 
consent to be randomised (n=38), a sample size of 40 
participants would allow us to estimate the true popula-
tion consent rate with a 11% margin of error (95% bino-
mial exact confidence level) for those meeting eligibility 
criteria. In line with recommended sample sizes of pilot 
feasibility trials,83–85 40 patients is deemed sufficient to 
explore feasibility, acceptability and potentially efficacy 
of the intervention, assuming retention rates of 80%, 
the true population consent rate will be with a margin 
of error of 13% (95% binomial exact CI), an acceptable 
level of error, based on the time, budget and workforce 
constraints, as FP will act as both the trial coordinator and 
therapist.
Analysis plan
Descriptive statistics of patients approached, screened, 
eligible, consented and randomised will be computed to 
address objectives 1–2. Reasons for non-consent, exclu-
sion and drop-out, at each stage of the study, will be 
recorded and reported. Adherence to the intervention 
will be reported using descriptive statistics to address 
objective 3. The following values will be computed: mean 
number of homework tasks completed, mean number 
of sessions completed, a breakdown on the number of 
participants completing each session, number of partic-
ipants completing the independent chapter, mean dura-
tion of the telephone and face-to-face sessions. SD by trial 
arm will be computed for the fatigue outcomes in order 
to estimate a more robust sample size for a future efficacy 
trial, thereby, addressing objective 4.
The psychometric quality of the self-report instru-
ments used will be assessed to address objective 5. Reli-
ability will be assessed using Cronbach’s alpha, with a 
minimum acceptable cut-off at α=0.70, but preferably at 
α=0.80 or higher, particularly for the key variables86 and 
individual items will be checked to ensure that there are 
no problematic items for this patient population. Conver-
gent validity will be assessed via Pearson’s correlations 
between psychological constructs (eg, depression and 
fatigue severity) and clinical markers (eg, comorbidities 
and fatigue severity). Additionally, content validity of the 
fatigue measures will be considered based on the quali-
tative data to ensure that the selected measures capture 
changes described by participants. Responsiveness/sensi-
tivity to change will be assessed by checking correlations 
between change scores on key variables of interest and by 
triangulation with participants' narratives.
Given the feasibility nature of the trial, statistical signif-
icance will not be assessed; instead effect sizes and CI 
will be estimated. An analysis of covariance (ANCOVA) 
will be performed to estimate the postintervention 
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mean difference in outcomes, controlling for the base-
line levels of each outcome, for the following variables: 
fatigue severity, fatigue-related functional impairment, 
depression, anxiety and subjective sleep quality, thereby 
addressing objectives 6 and 7. Group allocation will be 
included as an indicator variable following the inten-
tion-to-treat principle. Recruitment centre will also be 
controlled for in the analysis as it is a stratification factor. 
Differences in intervention effects by sociodemographic 
and clinical factors on fatigue outcomes will be explored.
Changes in fatigue perceptions, and cognitions and 
behaviours in response to fatigue will be evaluated via 
ANCOVAs to address objective 8. The proportion of 
the treatment effect that may be accounted for by these 
process variables with CI will also be calculated, as there 
will be insufficient power for mediation analyses.
To meet objective 9 and qualitatively explore the 
acceptability and usefulness of the intervention from the 
perspective of the participants, the semistructured quali-
tative interviews will be transcribed verbatim and analysed 
using inductive thematic analysis with the use of NVivo 
software. Thematic analysis revolves around identifying 
recurrent themes and patterns from the interviews and 
developing a coding manual.87
To address objective 10, a mixed methods approach will 
be used, drawing on both the quantitative and qualitative 
findings to determine any intervention-specific issues, 
such as the optimal number of sessions.
Considering issues relating to recruitment and reten-
tion rates, suitability of the selected measures, as well as 
any intervention-specific issues, will help us to determine 
whether to proceed to a full-scale efficacy trial, if so, these 
findings will also inform aspects of the design of the effi-
cacy trial, such as the required sample size and appro-
priate self-report measures to ensure sufficient power and 
sensitivity to detect any intervention effects.
dIsCussIon
Fatigue is common in chronic HD patients with conse-
quences on patients’ functioning and daily living, as well 
as implications on clinical outcomes. BReF is a theo-
ry-driven and evidence-based CBT intervention with 
therapist support aimed at improving renal fatigue, 
that has been designed following the Medical Research 
Council guidance for developing and evaluating complex 
interventions.88
This is the first feasibility RCT to examine whether a 
fatigue-specific CBT-based programme with therapist 
support is feasible, acceptable and possibly beneficial at 
reducing fatigue severity and fatigue-related functional 
impairment in patients undergoing in-centre HD who 
are fatigued. The brief and stepped structure of the inter-
vention may be more appropriate for patients receiving 
in-centre HD. Prior to proceeding to a full-scale trial, it 
is important to identify unique challenges with recruit-
ment and retention in this particular setting and to 
explore whether the content and structure of the manual 
are deemed useful and relevant by patients. The results 
of the BReF trial will inform the design of a future full-
scale trial powered to detect the efficacy of CBT for the 
management of fatigue in HD, accompanied by a longer 
follow-up to assess any sustained effects of the interven-
tion on outcomes.
Ethics
 The trial is co-sponsored by King’s College London and 
King’s College Hospital NHS Foundation Trust. Patient 
consent will be obtained. The Chief Investigator (CI) and 
all members of the research team will preserve the confi-
dentiality of participants taking part in the study and will 
work in accordance with the Caldicott Principles, Data 
Protection Act 1998, NHS Code of Confidentiality and 
any relevant NHS Trust organisational policies. All serious 
adverse events related to the study will be reported to the 
study sponsor, ethics committee and relevant NHS R&D 
departments. Authorisation will be sought from the study 
sponsor for any future substantial and non-substantial 
amendments arising during the course of the study, prior 
to submission to the HRA. The study may be subject to 
inspection and audit by King’s College London under 
their remit as sponsor and other regulatory bodies to 
ensure adherence to GCP and the NHS Research Gover-
nance Framework for Health and Social Care (second 
edition).
Indemnity
The study is cosponsored by King’s College London and 
King’s College Hospital, providing insurance for the 
study, through its own professional indemnity for research 
involving human participants and no fault compensation 
and the Trust having a duty of care to patients via NHS 
indemnity cover, in respect of any claims arising as a 
result of clinical negligence by its employees, brought by 
or on behalf of a study patient.
dissemination
We will endeavour to publish the findings of this trial in 
a peer-reviewed journal and present the findings at rele-
vant national and international conferences.
trial status
The study will start recruitment at the end of October 
2017. Recruitment will continue until July 2018. Patient 
involvement in the study will conclude in November 2018.
Contributors All authors contributed to the design of the study and writing of the 
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